Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

NCT03127592 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

140

Enrollment

INDUSTRY

Sponsor class

Stopped recruitment difficulty

Conditions

Pain, Acute

Interventions

DRUG: Fixed Dose Combination
DRUG: Etodolac
DRUG: Cyclobenzaprine

Sponsor

Apsen Farmaceutica S.A.